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Physio-pathologic interrelationships between endothelial layer and graft-versus-host disease (GVHD) 
have been described leading to assess the entity “endothelial GVHD” as the early step for clinical 
manifestations of acute GVHD. The availability of the CellSearch system has allowed us to monitor 
Circulating Endothelial Cells (CEC) changes in allogeneic hematopoietic stem cell transplantation 
(allo-HSCT) as useful tool to help clinicians in GVHD diagnostic definition. We have compared CEC 
counts generated by an ad hoc designed polychromatic-flowcytometry (PFC) Lyotube with those of 
the CellSearch system. CEC were counted in parallel at 5 timepoints in 50 patients with malignant 
hematologic disorders undergoing allo-HSCT (ClinicalTrials.gov, NCT02064972). Spearman rank 
correlation showed significant association between CEC values at all time points (p = 0.0001). The limits 
of agreement was demonstrated by Bland Altman plot analysis, showing bias not significant at T1, T3, 
T4, while at T2 and T5 resulted not estimable. Moreover, Passing Bablok regression analysis showed 
not significant differences between BD Lyotube and CellSearch system. We show that CEC counts, 
generated with either the CellSearch system or the PFC-based panel, have a superimposable kinetic in 
allo-HSCT patients and that both counting procedures hold the potential to enter clinical routine as a 
suitable tool to assist clinicians in GVHD diagnosis. 
 
 
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has strongly improved, over the past decades, 
the cure rate of several onco-hematologic diseases1. However, despite of these promising results, graft-versus-host 
disease (GVHD) remains one of the major factors influencing patients survival2,3. In fact, GVHD overall inci- 
dence ranges between 30% and 60% accounting for a 50% mortality rate, particularly in the more severe pres- 
entation4. Nowadays, GVHD diagnosis in routine clinics is still based on patient symptoms, clinicians expertise 
and affected tissues histology5. In order to reduce the need of invasive procedures, clinical researchers are hardly 
engaged in seeking specific and objective biomarkers in peripheral blood (PB) for improving GVHD diagnostic 
definition6. The recent definition of the physio-pathologic interrelationship between endothelium and GVHD 
has confirmed that vascular endothelium is an early target for donor T-lymphocytes7,8. Currently, circulating 
endothelial cells (CEC) are considered a specific and sensitive marker of endothelial damage in a variety of patho- 
logical conditions9–14. However, due to their rareness and complex phenotypes, no consensus on CEC identifica- 
tion and count has been so far fully obtained15–17. Therefore, the fine tuning of a standardized approach for CEC 
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identification and count could result crucial in order to move their monitoring into clinical practice. We recently 
joined a multicenter study (S.C.EN.I.C. Network: Standardization of Circulating ENdothelIal Cells) that, utiliz- 
ing a highly optimized method based on a polychromatic flowcytometry (PFC) Lyotube, proved the possibility 
to reach a high level standardization in CEC count and analysis18,19. Moreover, a physiological baseline range of 
CEC values has been provided for healthy subjects, becoming a valid reference in endothelial dysfunctions19. 
Today, CellSearch system represents the only commercially available procedure that guarantees standardization 
in CEC identification and count with high-level reproducibility, specificity and sensitivity10,13,14,20. We present the 
results of a comparative study of CEC counts (5 different timepoints) performed in parallel by means of an ad hoc 
designed PFC Lyotube and the CellSearch system in a cohort of 50 patients with malignant hematologic diseases 
undergoing allo-HSCT (ClinicalTrials.gov, NCT02064972). Although preliminary, our results can be the basis for 
future large-scale confirmatory study. 
Material and Methods 
Patients. Between June 2014 and October 2015, we prospectively analyzed 50 patients with malignant hema- 
tological disorders undergoing allo-HSCT. CEC counts were performed in parallel by means of two different 
methodologies: (1) polychromatic flow cytometry (PFC) using, all along the study, a single batch of pre-for- 
matted lyophilized-reagent tubes (Becton Dickinson, San Jose, CA, USA; Lyotube, Custom cat # 623920)18,19; 
(2) CellSearch system (Janssen Diagnostics LLC, Raritan, NJ, USA). The local research and ethics committee 
(Comitato Etico della Provincia di Brescia, document NP 1574 of the 14th January 2014 and Comitato Etico inter- 
aziendale AOU Città della Salute e della Scienza di Torino, document 0037975 of the 10th April 2014) approved 
the study protocol and all patients and controls provided written informed consent, in accordance with the 
Declaration of Helsinki. The trial was registered on ClinicalTrials.gov (NCT02064972). 
CEC counting was scheduled before and after conditioning regimen, at time of hematopoietic engraftment, 
at day +28 in the absence of GVHD, at time of GVHD onset and 1 week after steroid treatment. Day +28 was 
selected as a CEC counting timepoint in patients without GVHD, since the median time of GVHD onset in our 
previous series was 27 days14. Therefore, CEC values at day +28 in patients without GVHD were compared with 
CEC values at GVHD onset. Thus, CEC count during study was performed at the following five time points: 
T1 (pre-conditioning), T2 (pre-transplant), T3 (engraftment), T4 (GVHD onset or day +28), T5 (1 week after 
steroids). 
During study period, levofloxacin prophylaxis was continued until neutrophil recovery, and fluconazole/itra- 
conazole until immunosuppressive drugs has been suspended, while trimethoprim-sulphamethoxazole was used 
for Pneumocystis jirovecii prevention. Cytomegalovirus was weekly PCR monitored, and patients testing positive 
have received ganciclovir/foscarnet treatment. Fungal infections have been diagnosed according to published 
revised criteria21. GVHD diagnosis and grading were defined according to commonly accepted criteria22. 
 
Controls. Healthy volunteers (age 18 to 65 years) with normal blood parameters and pressure values served 
as controls. As previously reported19, healthy subjects were excluded if presenting at least one of the following 
parameters out of normality ranges12: blood pressure, glycaemia, cholesterol value. Smokers, healthy women 
within two weeks from menstrual period, individuals fasted within 12 hours, subjects with endometriosis, with 
active duodenal or gastric ulcer, HIV, HBV or HCV positive, subjects that received drug treatments in the preced- 
ing 48 hours or with present or previous neoplastic, infectious, inflammatory or cardiovascular diseases were also 
excluded. CEC counts were performed with CellSearch (n = 17) and with PFC (n = 21). 
 
Blood specimen collection. PB samples have been drawn from central catheter, in order to decrease risks 
of endothelial cell detachment due to traumatic damage from venipuncture. Samples for CellSearch count were 
collected in specifically dedicated tubes (CellSave Preservative Tubes, Janssen Diagnostics LLC, Raritan, NJ, 
USA), that guarantee the reproducibility of results up to 96 hours from blood drawn; while samples for PFC count 
were collected in three EDTA (2 mg/ml) tubes (BD K2E EDTA, Becton Dickinson Biosciences - BD, San Jose, CA, 
USA). Leukocyte count, determined on each first drawn tube, was used for double platform calculation. 
 
Polychromatic flowcytometry (PFC). CEC determinations were performed within 4 h from collec- 
tion18,19, with the purpose to avoid any detrimental effects on counting performance over time, as reported   
for both CEC19 and EPC23. As previously described18,19, PB volume containing 20 × 106 leukocytes underwent 
erythrocyte-lysis with 45 ml of Pharm Lyse solution (BD Biosciences), followed by centrifugation (400 g, 10 min, 
room temperature) and wash with 2 ml of Stain Buffer containing bovine serum albumin (BD Biosciences). 
Surface staining was accomplished by adding the resuspended pellet of each sample to the Circulating 
Endothelial Cell Lyotube kit (Becton Dickinson, Custom cat #623920) (Panel tube: CD146PE, CD34PE-Cy7, 
CD309AlexaFluor647, CD45APC-H7, 7AAD; Control tube: IsotypePE, CD34PE-Cy7, IsotypeAlexaFluor647, 
CD45APC-H7, 7AAD) and 1 µM Syto-16 (Thermo Fisher Scientific, Eisai, Medipost - US) was added as liquid 
drop-in. Samples incubated in the dark for 30 min at 4 °C were then washed (2 ml of Stain Buffer with BSA, BD 
Biosciences) and re-suspended in 1.5 mL of FACSFlow (BD Biosciences). Finally, 2–4 × 106 events/sample with 
lympho-monocyte morphology were acquired by flow cytometry (FACSCanto II, BD Biosciences). A threshold 
combination was set on FSC and FITC channel (Syto16) to exclude very small and non-nucleated events. Data 
were analyzed using FACSDiva v 6.1.3 (BD), and FACSuite v1.05 (BD Biosciences) and FlowJo v 8.8.6 (TreeStar, 
Ashland, OR) software. 
CEC were defined as 7-AADneg/syto16pos/CD45neg/CD34bright/CD146pos and counted by a dual-platform 
method applying the following formula18: 
  
 
 
CEC/mL = 
#CECpanel − #CECcontrol × #Total CD34panel/#Total CD34control 
× Lymphocyte Count × 1000
 
#Lymphocytepanel 
 
CellSearch System. CEC counts were performed, within 48 hours from collection, using the Circulating 
Endothelial Cell isolation kit (research use only) on the CellSearch system (Janssen Diagnostics LLC, Raritan, 
NJ, USA), allowing to standardize the process of sample collection, cellular selection, monoclonal antibodies 
labelling, analysis and enumeration of CEC10. CEC were defined as CD146+/CD105+/DAPI+/CD45− cells and 
their values expressed per mL of PB. 
Statistical Analysis. Standard descriptive statistics were used to summarize the patient sample. Continuous 
data were expressed as mean ± standard deviation and as median (range). Mann-Whitney U test was used in 
univariate analysis for comparison of continuous variables, and chi-squared test for comparison of categorical 
variables. Spearman’s rank correlation coefficient was calculated to estimate the association between PFC and 
CellSearch generated CEC values. The comparability between the two methods of CEC count (PFC Lyotube and 
CellSearch) was assessed by Passing Bablok regression analysis and by Bland Altman plot analysis. Passing Bablok 
regression analysis was used to detect constant or proportional differences between the two methods. In Bland 
Altman analysis, the mean of the differences between the paired measurements of the two methods (bias) and 
the limits of agreement were estimated. The limits of agreement defined the range within which 95% of the differ- 
ences were included. The bias was not significant if the 95% confidence interval of the mean difference included 
the value 0 (line of equality on the Bland Altman plot). 
For each method, a multivariate logistic regression analysis was performed at each time-point, to assess 
the correlation between GVHD and CEC values in the presence of possible interfering factors (i.e. patient and 
transplant-related variables, infectious events). The count of CEC/ml of PB and the relative increase of CEC val- 
ues at each time point (T) were included in all analyses. All p values were 2-sided and p < 0.05 was considered 
statistically significant. 
Results 
Allografting. We enrolled 50 patients with median age 51.5 years (range 18–69; 30 males and 20 females) 
undergoing allo-HSCT from either HLA-matched familial (n = 8; 16%), unrelated (n = 26; 52%) or haploidentical 
donor (n = 16; 32%) for their malignant hematologic disorders (24 AML, 10 ALL, 4 HD, 3 NHL, 1 CLL, 5 MDS, 3 
Chronic Myeloproliferative Disorders). At time of enrollment 29 patients (58%) were in complete response (CR), 
19 patients (38%) in partial response/CR > 1 and 2 patients (4%) in progression from their diseases. Thirty-nine 
(78%) patients received hematopoietic stem cells from mobilized peripheral blood and 11 (22%) from bone mar- 
row. The conditioning regimen was marrow-ablative in 30 patients (60%) and reduced intensity in 20 patients 
(40%). Engraftment was reached in 48 patients at a median time of 22 days (range 14–40); two patients died in 
aplasia, 1 from infection and 1 for toxicity (Table 1). No clinical and transplant differences were recorded between 
patients developing GVHD and those without GVHD, except for acute leukemia diagnosis (p = 0.03), haploiden- 
tical donor (p = 0.02) and F/Bu2 reduced conditioning (p = 0.03) (Supplemental Table S1). 20/50 patients (40%) 
presented GVHD at a median of 23 days (range 14–113) post-transplant. GVHD was grade I in 3/20 (15%), grade 
II in 16/20 (80%), grade III in 1/20 patients (5%), grade IV in 0/20 patients (0%), respectively. In 12/20 patients 
(60%) GVHD presented skin involvement, and in 10/20 patients (50%) gut involvement. 
CEC counting at baseline. The median CEC/ml in patients at T1 (pre-conditioning) was 24 (range 3–175) 
with PFC and 24 (range 2–786) with CellSearch (p = 0.63) in comparison to a value in healthy subjects of 13 
(range 2–57) (p = 0.005) and 2 (range 1–14) (p = 0.0001), respectively (Supplemental Fig. S1). 
CEC counting with polychromatic flow-cytometry. CEC counting in a representative patient at the 
five different timepoints is presented in Fig. 1. For a satisfactory identification and counting of CEC, a strategy 
based on a logical combination of gates is first applied on events displaying lympho-monocyte morphology, being 
alive (7-AAD neg) and nucleated (syto-16 pos) (Fig. 1, panel A, a–c). Afterward, cells being bright for CD34, 
negative for CD45 and positive for the endothelial cell marker CD146 (Fig. 1, panel B–F) are counted CEC. The 
corresponding raw data for calculating CEC values are reported in Supplemental Table S2. 
In PFC-generated CEC values, no differences were detected between patients developing GVHD and those 
without GVHD before (T1, pre-conditioning) and after the conditioning regimen (T2, pre-transplant). CEC val- 
ues neither changed in relation to age and sex at any timepoints (data not shown). At T1 (pre-conditioning) 
MDS/CMS patients had lower CEC values in comparison to acute leukemia (p = 0.0001) and Lymphomas/CLL 
patients (p = 0.001) (Fig. 2A). At T2 (pre-transplant) no differences in CEC values were recorded depending 
on diagnosis and conditioning regimen (MAC vs RIC), while patients receiving TBI-based conditioning reg- 
imen showed higher CEC values (p = 0.02) (Fig. 2C). At T3 (engraftment) no differences in CEC values were 
recorded depending on diagnosis, conditioning regimen, donor type and cells source (data not shown), while 
CyA/MTX GVHD prophylaxis was associated with higher CEC values (p = 0.03) (Fig. 2E). CEC values at T3 
resulted higher in patients without GVHD in comparison to patients developing GVHD (p = 0.01) (Fig. 3A). 
This difference remained significant in multivariate analysis by logistic regression model (OR 0.98, 95% C.I. 
0.97–0.99; p = 0.02). At T4 (day +28 or GVHD onset) patients with GVHD had higher CEC values in compari- 
son to patients without GVHD (p = 0.02) (Fig. 3A). This difference remained significant in multivariate analysis 
by logistic regression model (OR 0.98, 95% C.I. 0.97–0.99; p = 0.01). At T5 (1 week after steroids) CEC values 
returned to pre-transplant counts (data not shown). 
  
 
 
Characteristics Values % 
Age (years), median (range) 51.5 (18–69)  
Sex 
Male 30 60 
Female 20 40 
Diagnosis 
Acute Leukemias 34 68 
Lymphomas/CLL 8 16 
MDS 5 10 
CMS 3 6 
Disease status 
CR 29 58 
PR/CR >1 19 38 
Progression 2 4 
Donor 
MUD 26 52 
MRD 8 16 
Haploid 16 32 
HPC source 
MPB 39 78 
BM 11 22 
Conditioning regimen 
MAC 30 60 
RIC 20 40 
MA conditioning 
BU/CY 11 22 
FBu4 4 8 
TBI/CY 4 8 
TBI/F/Th 3 6 
TBF 8 16 
RIC conditioning 
Th/CY/F 2 4 
TBI/F/Th(r) 2 4 
FBu2 6 12 
Th/CY 5 10 
TBF(r) 4 8 
Th/F 1 2 
GVHD prophylaxis* 
CyA/MTX 33 66 
CyA/MMF 17 34 
ATG 19 38 
Engraftment 48 100 (48 evaluable patients) 
Time of engraftment (days), median (range) 22 (14–40)  
Table 1. Patients’ and transplant’s characteristics (n = 50). CLL: Chronic Lymphocitic Leukaemia, MDS: 
Myelodiplastic Syndrome, CMS: Chronic Myeloproliferative Syndromes, CR: complete remission, PR: partial 
remission, MUD: Matched Unrelated Donor, MRD: Matched Related Donor, Haploid: haploidentical related 
donor, MPB: Mobilised Peripheral Blood, BM: Bone Marrow, MAC: myeloablative conditinong, RIC: reduced 
intensity conditioning, BU: Busulphan, CY: Cyclophosphamide, F: Fludarabine, TBI: Total Body Irradiation, Th: 
Thiotepa, TBF: Th/BU/F, r: RIC, CyA: Cyclosporin A, MTX: Methotrexate, MMF: Mofetil Micofenolate, ATG: 
Anti-Lymphocyte Globulin. *In haploidentical transplantation GVHD prophylaxis included CyA/MMF and 
Cyclophosphamide post stem cell reinfusion (100 mg/kg total dose: day +3 and +5). 
 
 
CEC counting with CellSearch. In CellSearch generated CEC values, no differences were detected between 
patients developing GVHD and those without GVHD at any timepoints. CEC values neither changed in relation 
to age and sex at any timepoints (data not shown). At T1 (pre-conditioning) AL patients had higher CEC values 
in comparison to MDS/MCS (p < 0.05) and Lymphomas/CLL patients (p < 0.05) (Fig. 2A). At T2 (pre-transplant) 
no differences in CEC values were recorded depending on conditioning regimen (MAC vs RIC), while patients 
receiving TBI-based conditioning regimen showed higher CEC values (p = 0.01) (Fig. 2C). At T3 (engraftment) 
no differences in CEC values were recorded depending on conditioning regimen, donor type, cells source and 
  
 
 
 
 
Figure 1. Flow cytometry identification and count of CEC in PB samples of a representative patient. CEC 
were analyzed and counted in an AML patient (57 years), conditioned with Fludarabine/Bu4 regimen and 
receiving HPC-A from a matched unrelated donor (engraftment at day +28, skin GVHD diagnosed at day 
+45). Panel A: (a) Events showing lympho-monocyte morphology were gated in a FSC/SSC plot. (b) Dead cells 
were excluded because 7-AAD positive and afterwards (c) nucleated events were gated. Cells resulting from the 
logical combination of the three gates intersection were analyzed for CD45 and CD34 expression. Panel B–F: 
Two subpopulations, showing different levels of CD34 surface expression, were separately gated: CD34 positive 
cells, being CD45dim, represent the hematopoietic stem cell compartment (green dots), and CD34 bright cells, 
resulting CD45 negative (blue dots). Both subpopulations were than analyzed for CD146 expression (right 
column): CEC resulted CD34 bright/CD45 negative/CD146 positive (blue dots). The plot analysis are shown at 
the different timepoints during allo-HSCT (panel B: T1 pre-conditioning; panel C: T2 pre-Transplant; panel D: 
T3 engraftment; panel E: T4 GVHD onset; panel F: T5 1 week after steroids). The corresponding results of CEC 
calculations are shown in Supplemental Table S2. 
 
  
 
 
 
 
Figure 2. CEC counts during allogeneic hematopoietic stem cell transplantation. CEC counts performed with 
CellSearch (V) and with polychromatic flow cytometry (PFC) are shown on right and left column, respectively. 
CEC values at T1 (pre-conditioning) are shown in row (A) according to diagnosis, in row (B) to disease status, 
while CEC values at T2 (pre-transplant) are shown in row (C) according to conditioning, in row (D) to HPC 
donor, and CEC values at T3 (engraftment) are shown in row (E) according to GVHD prophylaxis. 
 
 
GVHD prophylaxis (data not shown). CEC values at T3 were relatively higher in patients without GVHD in 
comparison to patients developing GVHD (p = NS) (Fig. 3B). At T4 (GVHD onset or day +28) patients with 
GVHD had only few more CEC in comparison to patients without GVHD (p = NS) (Fig. 3B). At T5 (1 week after 
steroids) CEC values returned to pre-transplant counts (data not shown). 
  
 
 
 
 
Figure 3. CEC counts in patients with and without GVHD. CEC counts performed with PFC Lyotube (panel 
A) and with CellSearch System (panel B) at T3 (engraftment) and T4 (GVHD onset or day +28) timepoints. 
 
 
Comparison, correlation and degree of agreement between PFC and CellSearch. In the present 
study, we have compared CEC counts in allo-HSCT patients by means of two different methodologies (PFC 
Lyotube versus CellSearch). Spearman rank correlation analysis showed a significant association between the 
CEC values of the two methodologies at all time points (Table 2). The effective comparability between PFC 
Lyotube and CellSearch was assessed by Bland Altman plot analysis and Passing Bablok regression analysis. Bias 
and limits of agreement between the two methods of CEC count (Bland Altman plot analysis) at each time point 
are shown in Table 2. The bias between PFC Lyotube and CellSearch resulted not significant at T1, T3, T4. At T2 
and T5, the bias was not estimable, since the differences between the 2 methods were not normally distributed 
even after a logarithmic transformation of the data. Passing Bablok regression analysis showed not significant 
differences between CellSearch and PFC Lyotube except at T2 (Fig. 4). At T2 a significant deviation from lin- 
earity (p < 0.05) was observed, hence indicating that the Passing Bablok method is not applicable. However, 
when from the 25th patient onwards lymphocytes’ absolute numbers at T2 was PFC determined (CD45pos events 
in lympho-monocyte gate), no significant deviation from linearity can be recorded in the two splitted groups 
(patients 1–24 versus patients 25–50); moreover the regression line of CEC counts in patients from 25th to 50th 
showed a high comparability between CellSearch and PFC (Fig. 5). We thus confirmed that the lack was mainly 
related to the dual platform calculation procedure for PFC counts, being CEC determinations heavily affected at 
T2 by the unreliability of lymphocytes’ absolute numbers obtained by standard cell counter in a very deep leuko- 
penia phase. Despite of the significant correlation and the satisfactory degree of agreement between PFC Lyotube 
and CellSearch, the two CEC counting procedures maintain a fairly series of pros and cons, that makes them not 
mutually exclusive, but rather complementary (Table 3). The weaknesses of one CEC counting procedure are 
strengths of the other one and viceversa. 
Discussion 
CEC are rare cellular subpopulations in PB, detaching from vessel walls as a consequence of vascular damage 
or their physiological turnover. Together with endothelial progenitor cells (EPC) provide a measure of vascular 
health balance, being CEC markers of ongoing endothelial damage, whereas EPC informative of endothelial 
repair suitability9,11,12,24–28. In several clinical conditions, CEC counts have been exploited as valuable biomarkers 
to monitor vascular damage and treatment response9–14. However, due to their rareness and complex immunophe- 
notype, no consensus has yet been fully reached on their identification and way of count15–17. CEC count changes, 
as function of endothelial damage, have been reported in many different clinical conditions9–14. However, the 
translation of CEC counts into clinical practice has been weakened by the inconsistent results available till now. 
Recently, we joined the S.C.EN.I.C. network that developed a highly optimized PFC protocol for accurate CEC 
identification and count18,19, defining CEC as live and nucleated CD34bright/CD45neg/CD146pos events. Moreover, 
  
 
 
 
Time points 
CEC/ml  
p PFC Lyotube CellSearch 
T1 (pre-conditioning) 
Median (range) 
Mean ± SD 
24 (3–175) 
33.4 ± 32.9 
24 (2–786) 
59.7 ± 122.7 
 
0.63 
-Spearman rank correlation 
-Bland Altman plot analysis 
-r = 0.63; 95% C.I. (0.37–0.79) 
-limits of agreement (range)*: from −286.3 to 226.2 
mean difference (d^) (95% C.I.) = bias: −30.1 (−68.7–9.7) 
<0.0001 
bias not significant† 
T2 (pre-transplant) 
Median (range) 
Mean ± SD 
214.5 (16–19123) 
1046 ± 3313.1 
64 (8–718) 
114.3 ± 139 
 
0.0009 
-Spearman rank correlation 
-Bland Altman plot analysis 
-r = 0.63; 95% C.I. (0.32–0.80) 
-limits of agreement (range)*: from −4705.9 to 6029.2 
mean difference (d^) (95% C.I.) = bias: 661.6 (−116.7–1439.9) 
0.0001 
significance of bias not estimable 
T3 (engraftment) 
Median (range) 
Mean ± SD 
124 (30–670) 
145.5 ± 122.4 
85 (10–436) 
120.2 ± 89.6 
 
0.43 
-Spearman rank correlation 
-Bland Altman plot analysis 
-r = 0.79; 95% C.I. (0.61–0.88) 
-limits of agreement (range)*: from −129.5 to 166.3 
mean difference (d^) (95% C.I.) = bias: 18.4 (−3–39.8) 
<0.0001 
bias not significant† 
T4 (GVHD onset) 
Median (range) 
Mean ± SD 
104.5 (26–670) 
140.5 ± 112.6 
83 (13–658) 
127.5 ± 122.9 
 
0.38 
-Spearman rank correlation 
-Bland Altman plot analysis 
-r = 0.58; 95% C.I. (0.34–0.74) 
-limits of agreement (range)*: from −204.9 to 238.3 
mean difference (d^) (95% C.I.) = bias: 16.7 (−15.4–48.8) 
0.0001 
bias not significant† 
T5 (1 week after steroids) 
Median (range) 
Mean ± SD 
104.5 (26–670) 
121.3 ± 93.9 
64 (14–184 
85.3 ± 54.4 
 
0.27 
-Spearman rank correlation 
-Bland Altman plot analysis 
-r = 0.79; 95% C.I. (0.43–0.92) 
-limits of agreement (range)*: from −79.1 to 157.1 
mean difference (d) (95% C.I.) = bias: 39 (4.2–73.8) 
0.0008 
significance of bias not estimable 
Table 2. Comparison, correlation and degree of agreement between flowcytometry Lyotube and CellSearch 
for CEC count (n = 50 patients). *Limits of agreement = range within which 95% of the differences between the 
measurements of the two methods are included. d^ = mean of the differences between the paired measurements 
of the two methods. †The bias is not significant if the 95% confidence interval of the mean difference includes 
the value 0 (line of equality on the Bland Altman plot); in the BA analysis, differences between two methods 
(y) are plotted vs. the means of the two measurements (x); the bias (mean difference) is represented by the gap 
between the X axis, corresponding to zero differences between the 2 methods (line of equality), and the parallel 
line to the X axis at the value of the bias. 
 
 
a physiological baseline range for healthy subjects has been accounted, suitable as starting point for CEC mon- 
itoring in endothelial dysfunctions19. Reliability and reproducibility of S.C.EN.I.C. results have been conse- 
quently confirmed in a typical endothelial damage disease (i.e. diabetes)24 and in coronary artery disease patients 
(REMEDY clinical trial)25. Furthermore, by using the CellSearch system, we have just recently confirmed the role 
of CEC changes in the diagnostic definition of GVHD in the largest series of allo-HSCT patients20. Based on these 
assumptions, the aims of the present study were to (i) test an ad hoc designed PFC-based panel for CEC counting 
in the allo-HSCT setting; (ii) evaluate the agreement of the PFC-based panel with the validated CellSearch sys- 
tem; (iii) confirm that CEC changes in allo-HSCT patients represents a suitable tool to support clinicians in the 
GVHD diagnosis. The innovation of our study derives from the use of the validated and commercially available 
CellSearch system in comparison to an “ad hoc” designed novel polychromatic protocol using a lyophilized anti- 
body panel (BD Lyotube, Custom cat #623920), that proved to be the most reliable and suitable PFC method to 
count CEC, recently available on the market19. Even though clear phenotypic CEC definition has not yet reached 
widespread consensus, reasonable agreement has been proved between PFC and immunomagnetic-based meth- 
ods for CEC quantification in whole blood15,29. All together both methodologies still show a few issues; benefits 
and drawbacks have been in depth analysed by Goon et al.15, pointing out a caution against using both techniques 
interchangeably. By comparing CEC values (PFC Lyotube versus CellSearch) in allo-HSCT patients at the five dif- 
ferent timepoints, we have highlighted a significant comparability at all timepoints, except for the pre-transplant 
one (T2). This lack was mainly related to the dual platform calculation procedure for PFC counts, being CEC 
determinations heavily affected at T2 by the unreliability of lymphocytes absolute numbers obtained by standard 
cell counter in a very deep leukopenia phase. Thus, from the 25th patient onwards, lymphocytes absolute numbers 
at T2 was PFC determined using a dedicated TruCount tube (BD) containing CD45 and absolute counting beads 
(CD45pos events in lympho-monocyte gate). This modification allowed us to obtain a more satisfactory correla- 
tion between the two counting methods. It could be argued that a step forward in PFC counting improvement 
could be done by switching to a single tube assay, performing CEC identification and absolute count in the same 
step; however this approach would be limited by technical concerns related to the very high number of events to 
be acquired, fluorescences compliance and the essential washing step required by the PFC procedure. By extend- 
ing in wider details what reported in Table 3, CellSearch system has the great advantage, by using dedicated tubes 
(CellSave Preservative Tubes), to allow CEC counting within 96 hours from PB drawing, making it possible to eas- 
ily pull together samples from different days or to send them to a centralized lab-facility. Since CellSearch system, 
  
 
 
 
 
Figure 4. Linear correlation of CEC counts performed with CellSearch system and BD Lyotube (Custom cat 
# 623920). Linear correlation (Passing Bablok regression analysis) of CEC counts performed with CellSearch 
versus PFC (Lyotubes; BD Biosciences) at the different timepoints. Black line shows the regression line, dashed 
line the 95% C.I. of regression line, while dotted line represents the identity line (x = y). 
 
 
after on-board samples loading, operate in a fully automated manner, personnel can be used for different tasks 
during the three hours running time. Last but not least, CellSearch system provides results expressed in number 
of CEC per mL of PB without further calculations needed. The aforementioned aspects are anyhow counterbal- 
anced by a few unfavourable factors. CellSearch system, besides APC and PE fluorescence channels dedicated 
to anti-CD45 and anti-CD105, has only one more channel available, dedicated to FITC fluorescence detection. 
Therefore, availability of fluorescence combinations represents a fairly cumbersome limitation, particularly when 
dealing with phenotypically complex cellular events to identify. Moreover, since CellSearch system software oper- 
ates semi-automatically, capturing all images showing fluorescence signals in the PE channel, sometimes several 
thousands of images are presented to the operator for CEC identification and consequent count. Furthermore, 
personnel need to be specifically trained. Finally, it should not be forgotten the high costs for equipment purchase. 
On the other side, lights and shadows are present also for the PFC procedure. First of all, PFC gives the val- 
uable advantage to study additional antigens within the assay format (i.e. VEGFR2, for EPC identification and 
count) or easily to implement from the standard 6-color configuration up to combinations of 8–10 fluorescences, 
  
 
 
 
 
Figure 5. Linear correlation of CEC counts performed with CellSearch system and BD Lyotube (Custom 
cat # 623920) at T2 timepoint. Panel A shows the absence of correlation in the first 24 patients, in which the 
unreliability of lymphocytes absolute numbers obtained by standard cell counter in a very deep leukopenia 
phase, heavily affected the CEC counts determined by PFC. Intercept A = −905,7(−9816,8 to −112,6); 
slope B = 20,2 (6,5 to 155,6). Panel B shows the linear correlation from the 25th patient onwards, in which 
lymphocytes absolute numbers was PFC determined (CD45pos events in lympho-monocyte gate). Intercept 
A = 5,4 (−34,1 to 71,9); slope B = 1,8(1,2–2,37); not significant deviation from linearity (p > 0,05). Black line 
shows the regression line, dashed line the 95% C.I. of regression line, while dotted line represents the identity 
line (x = y). 
 
 
 Pros Cons 
 
CellSearch 
 
Analysis within 96 hrs 
Sample preparation/staining fully automated 
Single platform count 
Only one channel free for additional MoAb 
Occasionally high number of images (>10000) 
CEC counting semi-automated 
Need of specific training 
Highly expensive 
 
PFC Lyotube 
 
Highly performing 
Widespread platform availability 
Implementable (from 6-color standard) 
Sample staining/acquisition within 6 hrs 
Sample preparation/staining manually done 
Double platform count 
Highly trained personnel with expertise 
Time consuming for acquisition (4 M events) 
Table 3. Pros and cons of the two different CEC counting procedures. 
 
 
coupled with the prevention of CEC underestimation due to cell loss, because an immunological pre-enrichment 
step is avoided29. The widespread diffusion of PFC instruments makes accessibility to technology easy and imme- 
diate. The dark sides include the need to perform counting shortly after PB drawing, to avoid unpredictable 
decrease in CEC19 and EPC23 values overtime. Furthermore, cryopreservation exerts detrimental effects making 
CEC counting unreliable on thawed samples19. Highly trained personnel with expertise is required due to the 
rareness and complexity of cellular populations to be recognized and clearly identified; sample preparation and 
staining is done manually and sample acquisition and analysis (4 million events per sample), requiring accuracy 
and precision, is time consuming. By the end, the double platform count is heavily affected by deep leukopenia 
phase that, however, can be nicely solved by PFC determination of lymphocytes absolute numbers (CD45pos 
events in lympho-monocyte gate). 
  
 
The present study represents the only comparison trial, performed to date, that confirms the potential role of 
CEC count changes as a suitable tool to support clinicians in GVHD diagnosis. Our results strengthen the linear 
correlation between either methods, but furthermore points out the intrinsic limitations of each one procedure. 
Indeed, despite both techniques are considered suitable for CEC counting, they utilise fairly different analytical 
paths to provide results. Therefore, by taking into account the economic resources to be employed, we would rec- 
ommend either one procedure for supporting GVHD diagnosis in locally-based routine application, but in case of 
multicenter trial in more exploratory setting (i.e. chronic GVHD, veno-occlusive disease, idiopathic pneumonia 
syndrome) the use of both techniques could be advised. 
Although allo-HSCT is considered a potential curative therapy for patients affected by hematological disor- 
ders (i.e. malignancies, hematological deficiencies and immune disorders) and has improved the survival expec- 
tations of many patients, it is still not without risks, being GVHD the most life-threatening complication2–4. To 
date, no laboratory test can predict, on a routine basis, the risk of developing GVHD or the responsiveness to 
treatment. The availability of validated GVHD biomarkers, from PB samples, could result in an earlier identi- 
fication of patients burdened by higher risk of GVHD manifestations30,31. Consequently, patient identification 
will enable risk-adapted approaches to GVHD treatment, primarily implying an early and motivated switch to 
additional immunosuppressive therapies before the development of treatment unresponsiveness or refractori- 
ness. Moreover, the endothelial damage occurring during allo-HSCT might represent an emerging and intrigu- 
ing target for future studies involving preventive approaches32 or monitoring angiogenesis-inhibiting therapies. 
However, further studies on much larger patient numbers need to be performed in order to provide reliable and 
unquestionable answers to those issues. 
Data Availability 
The datasets generated and analyzed during the current study are available from the corresponding author on 
reasonable request. 
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